Story Highlight
– NHS England reviews private clinic agreements for gender care.
– Shared care agreements deemed risky for patient safety.
– GPs advised against prescribing for trans under-18s.
– Ongoing hormone treatments for adults may face future scrutiny.
– Criticism rises over NHS handling of trans healthcare access.
Full Story
NHS England is reevaluating its collaborations with private clinics that provide gender-affirming care for adults, amid concerns regarding patient safety and the regulation of these facilities. This consideration follows findings indicating that the lack of oversight in some private healthcare options may pose risks across all age groups.
The public health system is assessing whether general practitioners (GPs) should discontinue their partnerships with certain private clinics in prescribing hormones to adult patients, in light of the potential dangers associated with what it describes as “unregulated” services. Currently, GPs have the ability to implement a “shared care agreement,” a formal arrangement that enables them to prescribe various medications, including hormone treatments, with guidance from private providers.
Recent communications from NHS England have urged GPs to refrain from prescribing gender-affirming treatments to patients under 18 when using these private services. They are advised to recommend that patients and their families avoid medications procured from unregulated sources. Notably named in these advisories are GenderGP and Anne Trans Healthcare Limited, which are among the leading private clinics for transgender care in the UK.
Although the recommendations mainly pertain to under-18s, NHS England has indicated that it may consider expanding these guidelines to encompass adult patients in the future. The organisation’s newly released report states: “In recognition that unregulated healthcare services pose a potential risk to patient safety across all age ranges, NHS England will address the management of adults who source medications outside of the NHS-commissioned gender dysphoria service, including the management of those who are using atypical levels of medications, within its current work to establish a clinical commissioning policy for exogenous hormones in 2025/26.”
This motivational shift follows a history of abrupt prescription cancellations by GPs for transgender patients of various ages, as many medical practitioners have cited a lack of expertise in this area as a factor for their decisions. Despite these issues, it is important to note that numerous GPs continue to provide hormone therapy for cisgender adults and administer puberty blockers to minors experiencing conditions like precocious puberty or symptoms related to menopause.
Criticism has emerged concerning NHS England’s treatment of transgender healthcare, primarily from organisations advocating for the rights of transgender individuals. Tammy Hymas, policy leader at TransActual, expressed her discontent with NHS England’s decision to evaluate shared care agreements without addressing critical issues faced by gender identity clinics. She highlighted that prolonged wait times—sometimes exceeding eight years for initial appointments—force many individuals to seek care outside the NHS framework.
“It is disappointing that individuals are driven to find gender-affirming care from private providers when the NHS could readily resolve these delays.” Hymas urged for a system allowing access to gender-affirming care based on informed consent, which aligns with established practices and evidence supporting such an approach. “Currently, trans individuals are treated as if they are afflicted by a psychiatric disorder, which necessitates intrusive evaluations and complex bureaucracy,” she continued. “Everyone should enjoy autonomy over their own bodies, and this principle should equally apply to their access to hormone treatments.”
In a related development, an evidence review focusing on the efficacy of hormone replacement therapy (HRT) for transgender adults was announced—this was done in conjunction with NHS England’s decision to halt prescriptions of masculinising and feminising hormones for 16- to 17-year-olds. The review forms part of a broader commitment by NHS England, referenced in an Equality and Health Inequalities Impact Assessment report, to implement recommendations stemming from the 2024 report of Dr Hilary Cass.
Responding to the latest decisions from NHS England, Gender Plus, the country’s only regulated private transgender healthcare provider boasting an Outstanding rating from the Care Quality Commission (CQC), expressed disappointment. A spokesperson for the clinic characterised NHS England’s interpretation of evidence surrounding gender-affirming care as inconsistent with the prevailing views of reputable medical authorities. They stressed that the decisions contradict the consensus among global medical experts in this field.
Professor James Palmer, NHS England’s national medical director for specialised services, communicated that the forthcoming evidence reviews would give a clearer picture of whether the current approach to transgender healthcare warrants modification. “The NHS has taken a very cautious stance concerning the initiation of such treatments,” he remarked. “In light of this, we will be pausing all new referrals for 16- to 17-year-olds undergoing this treatment. Those already on these therapies within the NHS will continue, although their situations will be evaluated on an individual basis with their healthcare teams.”
As these developments unfold, stakeholders are keenly observing how NHS England’s decisions will shape the landscape of trans healthcare in the UK, as well as the potential impact on thousands of individuals seeking gender-affirming support. The ongoing debate reflects a larger conversation surrounding access to healthcare services, patient autonomy, and safety in medical practices that influence vulnerable populations.
Our Thoughts
The situation regarding shared care agreements for gender-affirming care raises significant health and safety concerns under UK legislation, particularly the Care Quality Commission (CQC) regulations and NHS guidelines. The potential risks associated with prescribing medications sourced from unregulated providers highlight the importance of adherence to proper regulatory frameworks to ensure patient safety.
To avoid the incidents described, NHS England could have implemented stricter oversight of private clinics engaged in shared care agreements. Enhanced vetting processes for these clinics based on CQC performance standards would have helped mitigate risks. Additionally, increasing capacity within NHS gender identity clinics to reduce waiting times could have prevented patients from seeking care from unregulated sources, thereby ensuring they receive safe and effective treatment.
Key lessons include the necessity of maintaining rigorous standards for all healthcare providers and ensuring equitable access to necessary medical care within the NHS framework. Regulations related to patient safety and care commissioning must be consistently applied and enforced to prevent similar future incidents. Enhanced communication between GPs and NHS England about the implications of prescribing practices is essential for ensuring patient safety across all age ranges.
